Qiagen NV, a European molecular diagnostics company, is drawing early takeover interest from private equity firms, according to people familiar with the matter cited by Bloomberg. The potential interest includes firms such as EQT AB and Advent. Investing.com also reports that early takeover discussions involve other well-known investment firms, naming KKR as among those showing interest, alongside EQT and Advent. The reports characterize the activity as preliminary, suggesting that discussions are at an early stage rather than indicating any confirmed bid, offer terms, or transaction timeline. Details on whether Qiagen is actively seeking a buyer, the size of any potential bids, or how far talks have progressed are not provided in the excerpts. No immediate comment from Qiagen is included in the provided text. The reporting therefore focuses on the existence of early interest from multiple investors rather than on the outcome of any formal process.